Telavancin is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Complicated skin and skin structure infections caused by susceptible Gram-positive bacteria (S. aureus including MRSA, S. pyogenes, other Strep species [S. agalactiae, S. anginosusgroup], or vancomycin sensitive E. faecalis).
- HAP and VAP caused by susceptible isolates of S. aureus.
- It should be reserved for use when alternative agents are not suitable.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- S. aureus bacteremia and right-sided endocarditis randomized trial comparing telavancin with standard therapy is under way (NCT02208063)
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: October 2, 2018
Citation
* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Telavancin
ID - 540538
A1 - Avdic,Edina,Pharm.D.
AU - Pham,Paul,Pharm.D. BCPS
Y1 - 2018/10/02/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540538/all/Telavancin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -